Enovis is the medical technology half of the old Colfax, reborn after the separation of the industrial welding unit, and the defining event of its current era is the January 2024 acquisition of LimaCorporate, a European orthopedic implant house bought at an enterprise value of 800 million euros in cash and stock. The deal roughly doubled the international implant base and turned Enovis into a two-segment orthopedics company, with Reconstructive carrying the growth and Prevention & Recovery supplying a cash-flow anchor that is, so far, mostly a drag. The second quarter of 2026 is the cleanest read yet on whether the rebuild is working, and the result is a top line growing on an organic basis, a Reconstructive segment in double-digit-adjacent reported growth, and a gross margin that expanded by two hundred thirty basis points against the year-ago quarter.
The argument for the stock runs through three variables: Reconstructive organic growth, gross-margin durability, and the pace at which the Lima integration stops bleeding cash and starts returning it. The argument against is equally legible. Prevention & Recovery is a commoditized consumer-brace business that shrinks when discretionary healthcare spending wobbles, the U.S. implant market is a brutal oligopoly, and the company carries a debt load of more than a billion in principal that keeps the GAAP income statement in the red through the maturity of the 2028 convertible notes. The market is pricing a modest success on the integration, not a failure, and the multiple on guided adjusted EBITDA sits in the mid single digits, which is a reasonable number for a medtech in the middle of an integration.
The base case of this report is that the Reconstructive growth holds and the margin expansion continues, and the base case implies a share value modestly above the current price. The bear case is that Prevention & Recovery keeps sliding and the U.S. implant share gain stalls, and the bear case implies a share value roughly half the current price. The stock is fairly valued for the company it is, the risk from the current level is asymmetric to the downside, and the single number that settles the debate is the Reconstructive organic growth rate in the next two quarterly reports.